Most treatments — like CPAP devices — blow air into the mouth. But an alternative technology sucks air instead. Is it onto something? Here’s what else you might have missed during your busy day. In the latest victory for President Donald Trump,

Nicotine vaping continues to outperform FDA-approved smoking cessation therapies in well-designed studies, including a new clinical trial conducted in Australia. This growing body of evidence badly undermines regulations that limit adult access to safer nicotine products that could save their lives.

Vaping was also better across subanalyses by age, sex, nicotine dependence, and mental illness and resulted in fewer patient-reported adverse events (incidence rate ratio 0.75, 95% CI 0.65-0.88), Ryan J. Courtney, PhD, of the University of New South Wales in Australia, and colleagues reported.

More adults with social disadvantage receiving 8-week vaporized nicotine products vs. nicotine replacement therapy achieved 6-month continuous smoking abstinence at a 7-month follow-up, according to study results.

The popularity of nicotine pouches is linked to a surge in nicotine poisoning among young children from the product, a new study suggests.

Because unpleasant withdrawal symptoms fuel nicotine addiction's high relapse rate, targeting their underlying mechanisms with treatments may promote continued abstinence from the drug.